558 related articles for article (PubMed ID: 29989279)
1. Letermovir successfully used for secondary prophylaxis in a heart transplant recipient with ganciclovir-resistant cytomegalovirus syndrome (UL97 mutation).
Chong PP; Teiber D; Prokesch BC; Arasaratnam RJ; Peltz M; Drazner MH; Garg S
Transpl Infect Dis; 2018 Oct; 20(5):e12965. PubMed ID: 29989279
[TBL] [Abstract][Full Text] [Related]
2. Successful Treatment of UL97 Mutation Ganciclovir-Resistant Cytomegalovirus Viremia in a Renal Transplant Recipient With Letermovir and Adjunct Hyperimmune Cytomegalovirus Immunoglobulin: A Case Report.
Pearston AP; Ingemi AI; Ripley K; Wilson TJ; Gruber J; McMahon M; Sutton S; Khardori N
Transplant Proc; 2021 May; 53(4):1284-1287. PubMed ID: 33715819
[TBL] [Abstract][Full Text] [Related]
3. Fast breakthrough of resistant cytomegalovirus during secondary letermovir prophylaxis in a hematopoietic stem cell transplant recipient.
Jung S; Michel M; Stamminger T; Michel D
BMC Infect Dis; 2019 May; 19(1):388. PubMed ID: 31068147
[TBL] [Abstract][Full Text] [Related]
4. Emergence of letermovir resistance in a lung transplant recipient with ganciclovir-resistant cytomegalovirus infection.
Cherrier L; Nasar A; Goodlet KJ; Nailor MD; Tokman S; Chou S
Am J Transplant; 2018 Dec; 18(12):3060-3064. PubMed ID: 30286286
[TBL] [Abstract][Full Text] [Related]
5. Successful Treatment with Letermovir in a Heart Transplant Recipient with UL97 Mutation Ganciclovir-Resistant Cytomegalovirus Colitis and Viremia.
Yanase T; Hatano M; Bujo C; Tsuji M; Ishida J; Amiya E; Okamoto K; Ando M; Shimada S; Kinoshita O; Fukushi S; Yamada S; Ono M; Komuro I
Int Heart J; 2023 Mar; 64(1):95-99. PubMed ID: 36682771
[TBL] [Abstract][Full Text] [Related]
6. New Locus of Drug Resistance in the Human Cytomegalovirus UL56 Gene Revealed by
Chou S; Satterwhite LE; Ercolani RJ
Antimicrob Agents Chemother; 2018 Sep; 62(9):. PubMed ID: 29914965
[TBL] [Abstract][Full Text] [Related]
7. Single-center experience with use of letermovir for CMV prophylaxis or treatment in thoracic organ transplant recipients.
Aryal S; Katugaha SB; Cochrane A; Brown AW; Nathan SD; Shlobin OA; Ahmad K; Marinak L; Chun J; Fregoso M; Desai S; King C
Transpl Infect Dis; 2019 Dec; 21(6):e13166. PubMed ID: 31487755
[TBL] [Abstract][Full Text] [Related]
8. Recurrent and persistent cytomegalovirus infection in a kidney recipient caused by the L595S mutation in UL97 phosphotransferase gene.
Peixoto M; Mascarenhas L; Cunha A; Dutra M; Miranda E; Silva I; Costa S; Galvão B; Cunha A
Antivir Ther; 2012; 17(3):585-8. PubMed ID: 22293247
[TBL] [Abstract][Full Text] [Related]
9. Use of high-dose ganciclovir for a resistant cytomegalovirus infection due to UL97 mutation.
West P; Schmiedeskamp M; Neeley H; Oberholzer J; Benedetti E; Kaplan B
Transpl Infect Dis; 2008 Apr; 10(2):129-32. PubMed ID: 17605740
[TBL] [Abstract][Full Text] [Related]
10. Letermovir Resistance Analysis in a Clinical Trial of Cytomegalovirus Prophylaxis for Hematopoietic Stem Cell Transplant Recipients.
Douglas CM; Barnard R; Holder D; Leavitt R; Levitan D; Maguire M; Nickle D; Teal V; Wan H; van Alewijk DCJG; van Doorn LJ; Chou S; Strizki J
J Infect Dis; 2020 Mar; 221(7):1117-1126. PubMed ID: 31781762
[TBL] [Abstract][Full Text] [Related]
11. Development of new cytomegalovirus UL97 and DNA polymerase mutations conferring drug resistance after valganciclovir therapy in allogeneic stem cell recipients.
Marfori JE; Exner MM; Marousek GI; Chou S; Drew WL
J Clin Virol; 2007 Feb; 38(2):120-5. PubMed ID: 17157554
[TBL] [Abstract][Full Text] [Related]
12. Ganciclovir susceptibilities and analysis of UL97 region in cytomegalovirus (CMV) isolates from bone marrow recipients with CMV disease after antiviral prophylaxis.
Erice A; Borrell N; Li W; Miller WJ; Balfour HH
J Infect Dis; 1998 Aug; 178(2):531-4. PubMed ID: 9697737
[TBL] [Abstract][Full Text] [Related]
13. Viral monitoring and successful treatment of a ganciclovir-resistant cytomegalovirus infection in a heart transplant recipient.
García-Martínez J; Folgueira L; Delgado R; Hernando S; Prieto C; Aguado JM; Otero JR
Transpl Infect Dis; 2008 Apr; 10(2):123-8. PubMed ID: 17605746
[TBL] [Abstract][Full Text] [Related]
14. An overview of letermovir: a cytomegalovirus prophylactic option.
Gerna G; Lilleri D; Baldanti F
Expert Opin Pharmacother; 2019 Aug; 20(12):1429-1438. PubMed ID: 31282759
[No Abstract] [Full Text] [Related]
15. Emergence of letermovir resistance in solid organ transplant recipients with ganciclovir resistant cytomegalovirus infection: A case series and review of the literature.
Hofmann E; Sidler D; Dahdal S; Bittel P; Suter-Riniker F; Manuel O; Walti LN; Hirzel C
Transpl Infect Dis; 2021 Jun; 23(3):e13515. PubMed ID: 33210830
[TBL] [Abstract][Full Text] [Related]
16. Incidence and outcomes of ganciclovir-resistant cytomegalovirus infections in 1244 kidney transplant recipients.
Myhre HA; Haug Dorenberg D; Kristiansen KI; Rollag H; Leivestad T; Asberg A; Hartmann A
Transplantation; 2011 Jul; 92(2):217-23. PubMed ID: 21685829
[TBL] [Abstract][Full Text] [Related]
17. Use of Letermovir as Salvage Therapy for Drug-Resistant Cytomegalovirus Retinitis.
Turner N; Strand A; Grewal DS; Cox G; Arif S; Baker AW; Maziarz EK; Saullo JH; Wolfe CR
Antimicrob Agents Chemother; 2019 Mar; 63(3):. PubMed ID: 30642941
[TBL] [Abstract][Full Text] [Related]
18. Combination Treatment With Letermovir and Ganciclovir for Maintenance Therapy of Multidrug-resistant CMV Infection in a Liver Transplant Recipient.
Kronig I; Elkrief L; Berney T; Van Delden C; Neofytos D
Transplantation; 2020 Aug; 104(8):e248-e249. PubMed ID: 32732860
[No Abstract] [Full Text] [Related]
19. Ganciclovir-resistant post-transplant cytomegalovirus infection due to combined deletion mutation at codons 595-596 of the UL97 gene.
Leung PYM; Tran T; Testro A; Paizis K; Kwong J; Whitlam JB
Transpl Infect Dis; 2019 Dec; 21(6):e13168. PubMed ID: 31498954
[TBL] [Abstract][Full Text] [Related]
20. Cytomegalovirus resistance in solid organ transplant recipients treated with intravenous ganciclovir or oral valganciclovir.
Boivin G; Goyette N; Rollag H; Jardine AG; Pescovitz MD; Asberg A; Ives J; Hartmann A; Humar A
Antivir Ther; 2009; 14(5):697-704. PubMed ID: 19704173
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
